First Southern California Practice to Join SpectraScience Network of Providers for the LUMA(R) Cervical Imaging System
SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that it has placed its LUMA Cervical Imaging System to detect pre-cancers at Women's Integrative Health, located in Encinitas, California.
Dr. Angelica Zaid, founder of Women's Integrative Health, stated, "We are pleased to be the first practice in Southern California to join the network of providers that now offer the LUMA Cervical Imaging System. In addition to enhancing our ability to detect and treat patients earlier who had abnormal Pap tests, the LUMA System fits into our practice goals of providing safe and non-invasive procedures for our patients."
SpectraScience CEO, Jim Hitchin, commented, "Women's Integrative Health is an important partner in our LUMA provider network. They focus on natural, safe approaches to Obstetrics, Gynecology & Fertility and place patient care as their highest priority. This placement represents our continued dedication in developing and bringing more effective cancer screening technologies to the market with the result of better and earlier diagnosis, thus saving lives."
The LUMA Cervical Imaging System was developed to significantly improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential to become invasive cancer. Almost a thousand women die every day worldwide from cervical cancer. Based on data from the National ALTS study, it is estimated that pre-cancerous disease goes undiagnosed in about 200,000 women each year. The LUMA System provides a safe and effective method, that when used as an adjunct to colposcopy, has been demonstrated to uncover at least 26% more high-grade pre-cancerous disease than colposcopy alone.
SpectraScience has filed for 60 patents worldwide on its WavSTAT(R) Optical Biopsy System and LUMA Cervical Cancer Imaging System that are used to diagnose tissue to determine within seconds if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA systems are currently approved by the FDA for detecting pre-cancer and cancer in the colon and cervix. A new application for detection of pre-cancers in the esophagus ("Barrett's esophagus") is being evaluated.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Contact: SpectraScience, Inc. Hayden Communications Jim Hitchin, Chief Executive Officer Investor Relations (858) 847-0200 x201 Todd Pitcher (858)-518-1387
|SOURCE SpectraScience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved